drugset / Trial / NCT03038451

Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients

NCT03038451

Phase 4 Completed 43 enrolled Neutec Ar-Ge San ve Tic A.Ş
NaSingle-groupOpen-labelTreatment

Summary

s-amlodipine besylate 2,5 mg tablet will be administered to patients have not received any hypertension treatment before or have received any of anti-hypertensive mono-therapy for the first four weeks of treatment. By increasing dose, s-amlodipine besylate 5 mg tablet will be administered for the last four weeks (4-8 weeks).

Timeline

Start
2013-03-20
Primary completion
2017-02-14
Completion
2017-02-14

Drugs

EvaluationDrugModalityDoseRoute
Subject S-amlodipine Unknown 5 mg

Indications